Skip to content
nadu.lk
Back to all politicians

Human immunoglobulin procurement case

Last verified 16 October 2026

Current status of the Human immunoglobulin procurement case

TRIAL ONGOING

Criminal prosecution arising from the procurement of substandard human immunoglobulin; a three-judge Trial-at-Bar was appointed and indictments were filed against Rambukwella and other accused.

What’s happened

Trial-at-Bar proceedings are active. He had previously spent months in remand before being released on bail.

Court
High Court Trial-at-Bar, Colombo
Next hearing / due
Next hearing not confirmed
Sources (4)
Alleged offence
Conspiracy and criminal misappropriation of public funds through the purchase of substandard immunoglobulin vials
Law / charge
13 counts: conspiracy, criminal misappropriation and aiding and abetting (per Sunday Times; not confirmed against the indictment)
Amount involved
About Rs. 144 million (some reports say Rs. 147 million); 6,195 vials reported
Court
Colombo High Court Trial-at-Bar (three judges, no jury)
Accused
Keheliya Rambukwella and 11 others, including ex-Health Secretary Janaka Chandragupta and supplier owner Sudath Janaka Fernando
Investigating agency
Criminal Investigation Department (CID); indictment filed by the Attorney General on 26 June 2025

What happened

In 2022, during Sri Lanka's economic crisis, the Health Ministry bought medicines under an Indian credit line. The Attorney General's case is that, around that period, officials changed procurement procedures and created an artificial shortage of drugs to justify buying stock (as reported by Ada Derana).

In October 2023 the National Medicines Regulatory Authority (NMRA) reported that a batch of human immunoglobulin vials, an antibody medicine, had failed quality tests and that forged documents had been used for Customs clearance. The Indian company named as the manufacturer reportedly told the NMRA it had not made or exported that batch.

The prosecution says the Medical Supplies Division of the Health Ministry received 6,195 vials of non-medicinal substances labelled as human immunoglobulin and Rituximab, and that more than Rs. 144 million of public money was misappropriated.

The charges

The indictment filed on 26 June 2025 contains 13 counts against 12 accused. Reports describe these as conspiracy, criminal misappropriation of state funds, and aiding and abetting. Sunday Times says the charges allege funds received under the Indian credit line were used to buy the substandard injections.

The accused include Keheliya Rambukwella, who was Health Minister at the time; former Health Ministry Secretary Janaka Chandragupta; the owner of the supplier company, Sudath Janaka Fernando; and several other health officials. Reports do not set out each accused person's individual role. These are charges, not findings; the accused are presumed innocent unless the court finds otherwise.

How it reached court

The CID began investigating after two complaints. Rambukwella was questioned several times, and on 2 February 2024 he was arrested and remanded, then later released on bail. He resigned as minister on 3 February 2024. According to Lanka Sara, the CID concluded its investigation after about one year and eight months.

In April 2025 the Attorney General asked the Chief Justice to appoint a Trial-at-Bar, a bench of three High Court judges sitting without a jury. Indictments were filed on 26 June 2025 and served in September 2025, when the defence argued bail applications and the Attorney General opposed bail.

In November 2025 a new bench was appointed after the original presiding judge retired and another was transferred. A pre-trial conference was fixed for 26 November 2025. One accused, Dr. Jayanath Buthpitiya, was reported to be overseas and subject to an arrest warrant.

Where it stands

The case is before the Trial-at-Bar and no verdict has been reported. The most recent available reporting is from November 2025 and concerns the pre-trial stage; no trial date or later hearing dates have been reported.

The prosecution has listed nearly 350 witnesses and about 300 documents and other productions. Rambukwella has publicly rejected wrongdoing in connection with the 2022 Indian credit line purchases, but no defence statement on the specific charges has been reported.

Separately, on 27 March 2026 the Supreme Court, in a civil fundamental-rights case about 2022 health-supplies purchases from a different supplier, found officials had breached the right to equality and ordered five respondents to pay Rs. 275 million in total, including Rs. 75 million from Rambukwella personally. That ruling does not concern the immunoglobulin charges.